45 results about "TetR" patented technology

The invention relates to a method for preparing a new material, particularly high-wearing and antistatic polyurethane material. The polyurethane material is formed by tetr-zinc oxide(T-ZnO)whisker and polyester polyol or polyether polyol, toluene diisocyanate(TDI) or methyl diphenylene diisocyanate(MDI) or p- phenyldiisocyanate(PPDI) and 3, 3'-dichlor-4, 4'- diaminodiphenylmethane(MOCA). The product can be got from the tetr-zinc oxide whisker through casting process after the decentralized and coupling processing. The invention is characterized by the unique and simple preparing process, the superior quality, high-wearing feature, high resistance to ripping, antistatic property, ageing and heating resistance; and the lower cost compared with the traditional polyurethane material. The product can be exclusively used in machinery, aerospace engineering, light industry, architecture, textile and mine engineering and so on.

The invention discloses a method for increasing the erythromycin yield by transforming the saccharopolyspora erythraea SACE_3980 gene. In saccharopolyspora erythraea, the gene SACE_3980 is subjected to transcription regulation by genetic engineering and through TetR-deficient family to obtain an engineering strain with high erythromycin yield; and by adopting the obtained strain for fermentation production of erythromycin, the yield can be remarkably increased, and a new technical support is provided for increasing the erythromycin yield in industrial production.

The invention discloses a method for improving erythrocin yield through a negative control gene SACE_3446 on an inactivation saccharopolyspora erythraea chromosome. Saccharopolyspora erythraea is used for producing erythrocin. The erythrocin and derived drugs of the erythrocin such as clarithromycin, azithromycin and telithromycin are used widely in clinic. Erythrocin high-producing strain screening is very important in industrial production. The erythromycin biosynthesis negative control gene SACE_3446 is screened from a saccharopolyspora erythraea TetR family. Compared with erythrocin yield of an original strain, deletion mutants of the saccharopolyspora erythraea SACE_3446 is improved remarkably, the erythrocin is returned to low yield after gene complementation of the SACE_3446, and therefore the SACE_3446 gene is a erythromycin biosynthesis negative control gene. The inactivation saccharopolyspora erythraea SACE_3446 gene can improve the erythrocin yield through a genetic engineering way. Due to the fact that erythromycin biosynthesis gene control is a network system, upstream and downstream control factors acted by SACE_3446 control factors can be found by using the SACE_3446 as an object. The erythrocin yield can also be improved by changing upstream or downstream control factor genes of the saccharopolyspora erythraea SACE_3446 control factors.

The present invention relates to a crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetr a-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide for inhibiting Btk, methods of preparation thereof and pharmaceutical compositions, and use of the crystalline form above in the treatment of a disease, or in the manufacturing of a medicament for the treatment of a disease.

The invention relates to expression systems useful for regulated expression of a gene of interest based on the constitutive expression of the original TetR repressor and the expression of the polynucleotide driven by a constitutive promoter operably linked to an operator sequence for a tetracycline operator sequence. The system can be provided as two different polynucleotides or as an all-in-one vector. The invention also relates to vectors, host cells and viral particles according to the invention as well as to the uses thereof for in vitro and in vivo production of products of interest or for therapy.

Mutant Listeria bacteria that modulate interferon-β production are provided. The subject bacteria are characterized by having a mutation in a gene chosen from a TetR gene, a LadR gene, a VirR gene, a MarR gene a MdrL gene, a MdrT gene and a MdrM gene. The subject bacteria find use in a variety of applications, where representative applications of interest include, but are not limited to: (a) use of the subject bacteria as adjuvants; (b) use of the subject bacteria as delivery vectors for introducing macromolecules into a cell; (c) use of the subject bacteria as vaccines for eliciting or boosting a cellular immune response; etc.

A transcriptional activator of T. gondii is provided which comprises the tetracycline repressor (TetR) operatively linked to a transacting factor of T. gondii. Strains of T. gondii transformed with a vector containing such a transactivator may be used to prepare vaccine compositions or to identify essential genes in the parasite. The system provided may be useful in other Apicomplexan species such as Plasmodium falciparum, Plasmodium vivax, Plasmodium berghei, Plasmodium yoelii, Plasmodium knowlesi, Trypanosoma brucei, Entamoeba histolytica, and Giardia lambia.

The invention discloses a protein TetR combinable with tetracycline and coding genes and applications of the protein TetR combinable with tetracycline. The protein which can be specifically combined with the tetracycline is (a) or (b): (a) is a protein composed by the amino acid sequence shown by sequence 1 in the sequence list, and (b) is a protein derived from (a) by subjecting the amido acid residue sequence of the sequence 1 in the sequence list to substitution and/or deletion and/or addition of one or multiple amido acid residues and by combination with tetracycline antibiotics. Recombined escherichia coli can be obtained by leading coding genes of tetracycline receptor protein into starting escherichia coli. The invention further discloses a method for preparing the protein, namely cultivation of the recombined strain. Experiments show that the method for preparing the tetracycline receptor protein is high in yield, and problems of low yield and difficulty in preparation in the prior art are solved, so that the method is of great importance.

The invention discloses a method for improving the yield of lincomycin through streptomyces lincolnensis regulation gene combination transformation. Strains are obtained by knocking out an Lrp familytranscription regulatory gene SLCG-4846 and a TetR family transcription regulatory gene SLCG-2919 from streptomyces lincolnensis in a combined manner. Meanwhile, the invention further discloses the method for improving the yield of lincomycin through streptomyces lincolnensis regulation gene combination modification. According to the method, traceless knockout is sequentially carried out on a plurality of genes through a homologous recombination technology, and resistance genes are not introduced in the process, so that the fermentation cost is reduced, and the hereditary stability is guaranteed. Meanwhile, the process does not influence the growth of thalli, and most importantly, multiple knockout experiments can be continuously carried out in the same strain. According to the method, theyield of lincomycin can be greatly increased, and a new technical support is provided for improving the yield of lincomycin in industrial production.

The invention provides a method capable of improving the homologous recombination efficiency of a CRISPR/Cas9 system and application. The CRISPR/Cas9 system comprises a Cas9-TetR fusion protein, guide RNA and a vector containing a tetracycline operon (tetO) element. The invention provides the method for carrying out homologous recombination by utilizing the CRISPR/Cas9 system. According to the method, a recombinant vector or Cas9 protein does not need to be subjected to additional chemical modification and purification, and the homologous recombinant vector only needs to be constructed into the skeleton vector containing the tetO element like conventional vector construction; the positive rate of homologous recombination of mediated DNA large fragments (more than 2000 base pairs) can be improved; and the homologous recombination positive rate can be improved by 2-3 times in the preparation of a gene modification animal model.

The invention discloses a conditionally replicating adenovirus vector for virus replication regulated by a TetR-KRAB-mediated transcription inhibition type Tet-On system, adenovirus E1 region comprises the following components in the following connection sequence: 5'-CMV promoter, TetR-KRAB gene, promoter TRE3G-E1b Pro containing a tetracycline responsive element, EcoR I enzyme cutting site, E1B Delta 55KD protein-deleted adenovirus E1A-E1B19KD gene sequence, enzyme cutting site Spe I and mRNA transcription termination signal SV40polyA-3'; the CMV promoter expresses transcription inhibitor TetR-KRAB; a gene sequence inserted into the two enzyme cutting sites of the EcoR I and the Spe I is a gene fragment from adenovirus E1A translation initiation site to adenovirus E1B19KD protein termination codon, the promoter TRE3G-E1b Pro containing the tetracycline responsive element expresses adenovirus E1A gene, adenovirus E1B19KD gene is expressed by the own promoter of the adenovirus E1B19KD, and the packed adenovirus is named as Ad5-CMV-TetR-KRAB-TRE3G-E1bPro-Delta 55KD. Tests show that the virus can be loaded into mesenchymal stem cells for application in study of tumor therapy.

The invention relates to a nucleic acid construct that comprises a human EF-1α promoter operatively associated with the tetracycline repressor (TetR). The invention further provides cell lines that have been stably transfected with such construct, as well as methods of using said construct, for the inducible expression of a transgene or for the inducible silencing of a endogenous sequence in mammalian cells.

The invention provides a self-clearing type adenovirus vector which is modified based on an AdEasyTM adenovirus vector system, wherein a used shuttle plasmid is pShuttle-CMV. The self-clearing type adenovirus vector is characterized in that the modification refers to inserting an rtetR (reverse tetR)-VP16 gene sequence, a TRE (Tetracyclin response element)-PminCMV-Cre gene sequence and two homodromous LoxP sites into the shuttle plasmid pShuttle-CMV. The self-clearing type adenovirus vector can be used for inducing adenoviruses to degrade and die at any time, can be used for eliminating exogenous genes and the adenovirus vector body before seed cells needed for tissue engineering are applied in vivo, and can be used for greatly lowering the quantity of the adenoviruses that enter the organisms to relieve influences of the vector on the organisms, so that a relatively safe and reliable vector is provided for a tissue engineering product.

The invention discloses an engineering strain for controlling adsorption and escape of heavy metals as well as a construction method and an application of the engineering strain. The engineering strain is a bacterium obtained by introducing a complete system into a host bacterium; the complete system comprises a heavy metal ion regulation protein, a heavy metal ion adsorption protein displayed on the surface of an ice nucleation protein, a streptavidin binding protein displayed on the surface of the ice nucleation protein and an escape control element, and the escape control element comprises repressor proteins PhlF, TetR, LacI and a lethal protein. Based on a synthetic biological technology, the invention provides a water body heavy metal adsorption and escape control microorganism which integrates the functions of heavy metal adsorption, microorganism enrichment after adsorption, escape control and the like in escherichia coli or pseudomonas putida, and the construction of a complex, fine and predictable genetic loop is realized by utilizing a standardized biological element; after optimization design, gene lines of adsorption, enrichment and death behaviors can be completed under the condition of mercury ions with different concentrations.

The invention discloses a tetracycline drug detection method based on TetR protein steric hindrance and a gene cleavage technology, a double-stranded DNA molecule for detecting tetracycline drugs, a composition, a kit and application of the double-stranded DNA molecule. The double-stranded DNA molecule comprises a tetracycline manipulating gene tetO and a restriction endonuclease recognition site, one end of the double-stranded DNA molecule is connected with a fluorophore, and the other end of the double-stranded DNA molecule is connected with biotin. The double-stranded DNA molecule can realize detection of tetracycline drugs.